MedTrace Logo

Arterial Ablation for the Treatment of Type 2 Diabetes Mellitus and Its Comorbidities

NCT05363761 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2023-03-21

No results posted yet for this study

Summary

This study is assess the safety and performance of the Neurotronic Infusion catheter for treatment of patients with Type 2 Diabetes (T2DM) and hypertension.

Conditions

Interventions

COMBINATION_PRODUCT

Neurotronic Infusion Catheter

Denervation of renal and common hepatic arteries by ethanol ablation with the Neurotronic Infusion Catheter

Sponsors & Collaborators

  • Libra Medical

    collaborator OTHER

  • Neurotronic, Inc.

    lead INDUSTRY

Principal Investigators

  • John Chen, PhD · Neurotronic, Inc.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
21 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-04-19
Primary Completion
2025-01-31
Completion
2029-01-31
FDA Drug
Yes
FDA Device
Yes

Countries

  • Panama
  • Paraguay

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05363761 on ClinicalTrials.gov